Although this seems to be a risky long trade. The reward is looking promising. Looking at the fundamentals, this company is well positioned with Cash. Debt is manageable even though the company is burning through cash (but that what most healthcare companies do until their products get FDA approval). Targets and Stops are in the graphic.
Trade active
Trade active
Trade active